Study study type PathologyT1T0Patientssample sizesROB Results

mBC - TNBC - L2 - PDL1 positive breast cancer - triple negative mBC-Triple negative (TNBC) - 2nd Line (L2) mBC - TNBC - L2 - PDL1 positive

versus Standard of Care (SoC)
pembrolizumab alone
KEYNOTE-119 (PDL1 CPS>1), 2019
  NCT02555657
RCTmBC - TNBC - L2 - PDL1 positivePembrolizumabchemotherapy (single agent)patients with previously treated metastatic triple negative breast cancer (mTNBC) patients with PDL1 CPS> 1 only203 / 202some concern
inconclusive
  • inconclusive 14 % decrease in deaths (OS),deaths (OS) (PE)
  • statistically significant 35 % increase in progression or deaths (PFS),progression or deaths (PFS)
KEYNOTE-119 (PDL1 CPS>10), 2019
  NCT02555657
RCTmBC - TNBC - L2 - PDL1 positivePembrolizumabchemotherapy (single agent)patients with previously treated metastatic triple negative breast cancer (mTNBC) patients with PDL1 CPS> 10 only96 / 98some concern
inconclusive
  • inconclusive 22 % decrease in deaths (OS),deaths (OS) (PE)